Research
Hormonal
GLP-1 receptor agonists have shown early evidence of cardiovascular benefits in obese patients.
GLP-1 RAs may also be beneficial for cardiovascular health in obese patients.
StrongSupportsmedium confidence
In addition to their role in weight loss, these drugs have shown promising early evidence of cardiovascular benefits in obese patients.
Why this rating
The claim is based on early evidence discussed in the review.
Source
Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: A review
Fatima Ali Raza et al. · Medicine · 2024
reviewCited 12×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →